Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Tryptamine Therapeutics ( (AU:TYP) ) has shared an announcement.
Tryptamine Therapeutics has established a framework for a world-first clinical trial to treat Binge Eating Disorder (BED) using TRP-8803, in collaboration with Swinburne University. The trial aims to assess the safety and efficacy of TRP-8803, administered with psychotherapy, in BED patients, potentially impacting the treatment landscape for this prevalent disorder in the US and Australia.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing TRP-8803, a proprietary psilocin-based, IV-infused formulation with neuroplastic benefits.
Average Trading Volume: 1,474,349
Technical Sentiment Signal: Sell
Current Market Cap: A$46.05M
Find detailed analytics on TYP stock on TipRanks’ Stock Analysis page.